相关实验视频
Updated: Jul 6, 2025

07:09
The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
Published on: July 16, 2014
48.2K
长期使用上腺激素激动剂调节可感性离子通道
Aline S Medrado1, Naiara A S Santiago1, Eder R Moraes1
1Department of Physiology and Biophysics, Institute of Biological Sciences-ICB, Federal University of Minas Gerais-UFMG., Av. Antônio Carlos, 6627, Pampulha, Belo Horizonte, Minas Gerais, Zip-code: 31270-901, Brazil.
Neuroscience letters
|January 8, 2024
概括
上腺体介质在背部根 (DRG) 神经元中差异调节疼痛信号. 慢性刺激会影响ATP激活通道和素激活的TRPV1通道,影响基于上腺素受体亚型的感觉.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 背部根腺 (DRG) 神经元传递感官信息.
- 上腺体介质影响神经元刺激性和恶感.
- 由ATP引入的P2X和由素引入的TRPV1通道是疼痛转导的关键.
研究的目的:
- 研究上腺素受体激活对DRG神经元离子通道的长期影响.
- 确定不同上腺素受体亚型如何调节感知信号.
主要方法:
- 在试验室中,DRG神经元的初级培养被选择性上腺激动剂激发.
- 电生理学记录评估了ATP和素激活电流.
- 神经元刺激性是通过基的变化来衡量的.
主要成果:
- α1-上腺激动剂增加了缓慢的ATP激活电流,但不是快速电流或素电流.
- α2,β1和β3-上腺激动剂降低了素激活电流,但没有影响ATP电流.
- 上腺激素调节没有改变神经元质基,这表明特定的道效应.
结论:
- 慢性上腺激活在DRG神经元中差异调节P2X和TRPV1通道功能.
- 特定的上腺素受体亚型决定了 nociceptive 信号是否增加或减少.
- 这些发现提供了对上腺体信号在疼痛和镇痛中的复杂作用的洞察.
相关概念视频
Analgesia and Pain Management
625
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
625
Nociception
27.9K
Nociception—the ability to feel pain—is essential for an organism’s survival and overall well-being. Noxious stimuli such as piercing pain from a sharp object, heat from an open flame, or contact with corrosive chemicals are first detected by sensory receptors, called nociceptors, located on nerve endings. Nociceptors express ion channels that convert noxious stimuli into electrical signals. When these signals reach the brain via sensory neurons, they are perceived as pain.
27.9K
Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.2K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.2K
Adrenergic Agonists: Indirect-Acting Agents
1.6K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.6K
Adrenergic Neurons: Neurotransmission
3.8K
Postganglionic sympathetic fibers (except those supplying the sweat glands) releasing noradrenaline or norepinephrine are called noradrenergic or adrenergic neurons. Noradrenaline, dopamine, adrenaline, or epinephrine are collectively called "catecholamines" as they contain a catechol moiety and an amine side chain. The five stages of neurotransmitter release involve their synthesis, storage, release, reuptake and metabolism.
Synthesis: Catecholamine synthesis requires tyrosine, which...
Synthesis: Catecholamine synthesis requires tyrosine, which...
3.8K
Drugs Acting on Autonomic Ganglia: Stimulants
1.3K
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
1.3K

